Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
I-Falmin is a specialized nutraceutical and phytopharmaceutical candidate derived from the extract of the toman fish (*Channa micropeltes*), a species native to Southeast Asia known for its high protein and albumin content. The product is primarily utilized to address hypoalbuminemia and support recovery in patients suffering from chronic infections like pulmonary tuberculosis, malnutrition, and post-operative wounds. Its therapeutic profile is driven by concentrated levels of albumin, which helps maintain plasma oncotic pressure and serves as a carrier for various ligands, alongside essential amino acids and omega-6 fatty acids (such as arachidonic acid) that facilitate tissue repair and modulate immune responses. Developed by PT Ismut Fitomedika Indonesia, I-Falmin is currently registered as a traditional herbal medicine in Indonesia and is undergoing clinical evaluation (e.g., NCT07186478) to validate its efficacy as an adjunctive therapy for tuberculosis-associated nutritional recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on I-Falmin.